POZEN starts enrollment for phase 3 studies for PA32540
POZEN announced the start of enrollment for the phase 3 studies for PA32540. PA32540 is a fixed-dose combination of 325 mg of enteric coated aspirin and 40 mg of immediate release omeprazole, under investigation for use in the secondary prevention of heart attacks and strokes in patients at risk for associated gastric ulcers. :theflyonthewall.com
News For POZN From The Last 14 Days
Check below for free stories on POZN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
